With a number As more people are fully vaccinated against COVID-19, pedestrian traffic and tourism in Las Vegas are picking up, and Planet 13 is taking advantage. The jar company reported a record monthly revenue of $ 9.7 million in March. He broke this record in April with a c$ 10.7 million in business. It broke that record again in May with monthly sales of $ 11.2 million.
Planet 13 recently opened another supermarket in California, the largest state in the United States. United in terms of population. The company has ambitions to open more of these cannabis-focused entertainment complexes in major cities across the United States, including New York City, Washington D.C. and miami.
This master plan is not guaranteed to work. The cannabis industry in the United States is very competitive, with several companies expanding their footprint in more than a dozen states. Some of these companies generate much higher quarterly revenue and profit than Planet 13. In addition, opening these new stores in other states will cost money and additional expenses once they are closed. 'they will be operational.
Management The objective of opening moreEight new supermarkets over the next five years may be achievable, and the company is betting those stores will be as successful as the one in Las Vegas - which is by no means a safe bet. Planet 13 remains a small-cap company with a market cap of just $ 1.2 billion, and that's after its shares have climbed 184% in the past year.
If Planet 13 continues to execute his long term plan, those who buy this cannabis stock today will be glad we did later.
Image source: Images
2. Cassava Sciences
Shares of clinical-stage biopharmaceutical company Cassava Sciences have increased by 3.285% in the last year. What lies behind this performance? Simufilam has produced promising data in clinical trials. In a phase 2b study, the results of which were announced by Cassava Sciences in September 2020, simufilam has been shown to improve several biomarkers of Alzheimer's disease in patients with the disease
According to the company, "the ability to "Improving multiple biomarkers from separate biological pathways with a single drug has never been demonstrated before in patients with Alzheimer's disease."An interim review of an open label study of simufilam. The drug has successfully improved cognition and behavior in AD patients.
While these results are encouraging in themselves, investors have also become interested in cassava science due to the recent controversial approval of drug Aduhelm from Biogen . Simufilam does not work the same way as Aduhelm - the latter focuses on removing amyloid plaques in the brain (some experts believe that the build-up of beta-amyloid protein is one of the causes disease). Meanwhile, simufilam is designed to restore the normal form and function of filamin A, a brain protein that in altered form is believed to be linked to AD.
So what? makes Cassava Sciences risky to buy?
Prior to the approval of Aduhelm from Biogen, there wasThis is a long list of unsuccessful attempts to develop effective treatments for AD - and some of these potential drugs have also produced excellent results in phase 2 studies. Aduhelm became the first AD drug approved since 2003. And even then, some experts believe this decision by the US Food and Drug Administration (FDA) was wrong.
At least three members of an independent panel convened last year by the regulatory body to discuss Aduhelm resigned from their post as a result of drug approval. The potential failure of clinical trials is always a risk that biotech investors should be concerned about. But in this case, the risk seems significantly higher than normal, although that also means that the potential rewards could be huge.
Cassava Sciences has announced that it will launch a study.e phase 3 for its main candidate in the second semester. of the year. The trial "will assess the disease modifying effects of simufilam in Alzheimer's disease." The results could arrive sometime in the next year. If they are positive, expect Cassava Sciences shares to skyrocket. But if they are negative, the company's shares could fall off a cliff. Investors comfortable with risk should consider starting a (small) position in this health care security.